Incidence of and Risk Factors for Cataract in Anterior Uveitis.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
10 2023
Historique:
received: 09 08 2022
revised: 13 06 2023
accepted: 13 06 2023
pmc-release: 01 10 2024
medline: 26 9 2023
pubmed: 7 7 2023
entrez: 6 7 2023
Statut: ppublish

Résumé

To estimate the incidence/risk factors for cataract in noninfectious anterior uveitis. Retrospective multicenter cohort study (6 US tertiary uveitis sites, 1978-2010). Data were harvested by trained expert reviewers, using protocol-driven review of experts' charts. We studied cataract incidence-newly reduced visual acuity worse than 20/40 attributed to cataract; or incident cataract surgery-in 3923 eyes of 2567 patients with anterior uveitis. Cataract developed in 507 eyes (54/1000 eye-years, 95% CI 49-59). Time-updated risk factors associated with cataract included older age (≥65 vs <18 years: adjusted hazard ratio [aHR] 5.04, 95% CI 3.04-8.33), higher anterior chamber cell grade (P(trend)=0.001), prior incisional glaucoma surgery (aHR 1.86, 95% CI 1.10-3.14), band keratopathy (aHR 2.23, 95% CI 1.47-3.37), posterior synechiae (aHR 3.71, 95% CI 2.83-4.87), and elevated intraocular pressure ≥30 vs 6-20 mm Hg (aHR 2.57, 95% CI 1.38-4.77). Primary acute (aHR 0.59, 95% CI 0.30-1.15) and recurrent acute (aHR 0.74, 95% CI 0.55-0.98) had lower cataract risk than chronic anterior uveitis. Higher-dose prednisolone acetate 1%-equivalent use (≥2 drops/day) was associated with >2-fold higher cataract risk in eyes with anterior chamber cell grades 0.5+ or lower but was not associated with higher cataract risk in the presence of anterior chamber cells of grade 1+ or higher. Cataract complicates anterior uveitis in ∼5.4/100 eye-years. Several fixed and modifiable risk factors were identified, yielding a point system to guide cataract risk minimization. Topical corticosteroids only were associated with increased cataract risk when anterior chamber cells were absent or minimally present, suggesting their use to treat active inflammation (which itself is cataractogenic) does not cause a net increase in cataract incidence.

Identifiants

pubmed: 37414328
pii: S0002-9394(23)00262-3
doi: 10.1016/j.ajo.2023.06.021
pmc: PMC10528977
mid: NIHMS1916252
pii:
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

221-232

Subventions

Organisme : NEI NIH HHS
ID : R21 EY026717
Pays : United States
Organisme : NEI NIH HHS
ID : R56 EY014943
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY022445
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY032592
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY014943
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Références

Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Am J Ophthalmol. 2010 Oct;150(4):534-542.e2
pubmed: 20643395
Am J Ophthalmol. 2021 Sep;229:200-209
pubmed: 33713679
Arch Ophthalmol. 2004 Apr;122(4):487-94
pubmed: 15078665
Am J Ophthalmol. 2000 Oct;130(4):492-513
pubmed: 11024423
Ocul Immunol Inflamm. 2019;27(7):1105-1113
pubmed: 30142008
Am J Ophthalmol. 2012 May;153(5):932-8
pubmed: 22265149
Am J Ophthalmol. 2003 Feb;135(2):231-2
pubmed: 12566033
JAMA. 2017 May 16;317(19):1993-2005
pubmed: 28477440
Am J Ophthalmol. 2008 Dec;146(6):813-8.e1
pubmed: 18687418
Arch Soc Esp Oftalmol (Engl Ed). 2019 Feb;94(2):60-74
pubmed: 30528895
Diabetes Metab Res Rev. 2019 Jan;35(1):e3073
pubmed: 30209868
Klin Monbl Augenheilkd. 1993 Apr;202(4):269-80
pubmed: 8331883
Ophthalmology. 2014 Nov;121(11):2275-86
pubmed: 25017415
Curr Opin Ophthalmol. 2020 May;31(3):167-173
pubmed: 32175941
Ophthalmology. 2014 Aug;121(8):1643-8
pubmed: 24697913
Int Ophthalmol. 1990 Oct;14(5-6):303-8
pubmed: 2249907
Cardiovasc Ther. 2018 Dec;36(6):e12480
pubmed: 30597753
BMJ. 2009 Jul 03;339:b2480
pubmed: 19578087
Ophthalmic Epidemiol. 2008 Jan-Feb;15(1):47-55
pubmed: 18300089
Ophthalmology. 2017 Aug;124(8):1196-1208
pubmed: 28433444
Ocul Immunol Inflamm. 2019;27(3):484-496
pubmed: 29260952
Br J Ophthalmol. 2019 Nov;103(11):1561-1565
pubmed: 30733210

Auteurs

George N Papaliodis (GN)

From the Department of Ophthalmology, Massachusetts Eye and Ear Infirmary (G.N.P., J.H.K.), Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School (G.N.P., C.S.F., J.H.K.), Boston, Massachusetts, USA. Electronic address: george_papaliodis@meei.harvard.edu.

Bernard A Rosner (BA)

Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (B.A.R.), Boston, Massachusetts, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health (B.A.R.), Boston, Massachusetts, USA.

Kurt A Dreger (KA)

Department of Population, Family, and Reproductive Health, Johns Hopkins Bloomberg School of Public Health (K.A.D.), Baltimore, Maryland, USA; Department of Ophthalmology, Johns Hopkins School of Medicine (K.A.D., J.E.T., D.A.J.), Baltimore, Maryland, USA.

Tonetta D Fitzgerald (TD)

Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine (T.D.F., N.P.B., G.-s.Y., s.k.), Philadelphia, Pennsylvania, USA.

Pichaporn Artornsombudh (P)

Massachusetts Eye Research and Surgery Institution (P.A., S.K., C.S.F.), Waltham, Massachusetts, USA; Department of Ophthalmology, Somdech Phra Pinklao Hospital, Royal Thai Navy (P.A.), Bangkok, Thailand;; Department of Ophthalmology, King Chulalongkorn Memorial Hospital (P.A.), Bangkok, Thailand.

Srishti Kothari (S)

Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine (T.D.F., N.P.B., G.-s.Y., s.k.), Philadelphia, Pennsylvania, USA; Massachusetts Eye Research and Surgery Institution (P.A., S.K., C.S.F.), Waltham, Massachusetts, USA.

Sapna S Gangaputra (SS)

Vanderbilt Eye Institute, Vanderbilt University Medical Center (S.S.G.), Nashville, Tennessee, USA.

Grace A Levy-Clarke (GA)

Department of Ophthalmology and Visual Sciences, West Virginia University (G.A.L.-C.), Morgantown, West Virginia, USA.

Robert B Nussenblatt (RB)

Laboratory of Immunology, National Eye Institute, National Institutes of Health (R.B.N., H.N.S.), Bethesda, Maryland, USA.

James T Rosenbaum (JT)

Department of Ophthalmology, Oregon Health and Science University (J.T.R., E.B.S.), Portland, Oregon, USA; Department of Medicine, Oregon Health and Science University (J.T.R.), Portland, Oregon, USA; Legacy Devers Eye Institute (J.T.R.), Portland, Oregon, USA.

H Nida Sen (HN)

Laboratory of Immunology, National Eye Institute, National Institutes of Health (R.B.N., H.N.S.), Bethesda, Maryland, USA.

Eric B Suhler (EB)

Department of Ophthalmology, Oregon Health and Science University (J.T.R., E.B.S.), Portland, Oregon, USA; Portland Veteran's Affairs Medical Center (E.B.S.), Portland, Oregon, USA.

Jennifer E Thorne (JE)

Department of Ophthalmology, Johns Hopkins School of Medicine (K.A.D., J.E.T., D.A.J.), Baltimore, Maryland, USA; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health (J.E.T., D.A.J.), Baltimore, Maryland, USA.

Nirali P Bhatt (NP)

Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine (T.D.F., N.P.B., G.-s.Y., s.k.), Philadelphia, Pennsylvania, USA.

C Stephen Foster (CS)

Department of Ophthalmology, Harvard Medical School (G.N.P., C.S.F., J.H.K.), Boston, Massachusetts, USA; Massachusetts Eye Research and Surgery Institution (P.A., S.K., C.S.F.), Waltham, Massachusetts, USA.

Douglas A Jabs (DA)

Department of Ophthalmology, Johns Hopkins School of Medicine (K.A.D., J.E.T., D.A.J.), Baltimore, Maryland, USA; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health (J.E.T., D.A.J.), Baltimore, Maryland, USA.

Clara M Pak (CM)

University of Rochester School of Medicine & Dentistry (C.M.P.), Rochester, New York, USA; MCM Eye Unit, MyungSung Christian Medical Center (MCM) General Hospital and MyungSung Medical School (J.H.K., C.M.P.), Addis Ababa, Ethiopia.

Gui-Shuang Ying (GS)

Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine (T.D.F., N.P.B., G.-s.Y., s.k.), Philadelphia, Pennsylvania, USA.

John H Kempen (JH)

From the Department of Ophthalmology, Massachusetts Eye and Ear Infirmary (G.N.P., J.H.K.), Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School (G.N.P., C.S.F., J.H.K.), Boston, Massachusetts, USA; MCM Eye Unit, MyungSung Christian Medical Center (MCM) General Hospital and MyungSung Medical School (J.H.K., C.M.P.), Addis Ababa, Ethiopia; Department of Ophthalmology, Addis Ababa University School of Medicine (J.H.K.), Addis Ababa, Ethiopia. Electronic address: john_kempen@meei.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH